Table 3.
Baseline patient characteristics and the association with clinical outcome and RR (Ethnicity was self-defined by the patients)
| RR | PFS | OS | |||||
|---|---|---|---|---|---|---|---|
| n | % | CR/PR | SD/PD | HR (95%CI) | HR (95%CI) | ||
| Sex | |||||||
| Female | 57 | 43 | 23(41%) | 33(59%) | 1 (Reference) | 1 (Reference) | |
| Male | 75 | 57 | 41 (58%) | 30 (42%) | 0.64 (0.44, 0.93) | 0.78 (0.50, 1.22) | |
| P value | 0.075 | 0.016 | 0.27 | ||||
| Age, years | |||||||
| <55 | 53 | 40 | 23 (44%) | 29 (56%) | 1 (Reference) | 1 (Reference) | |
| 55–64 | 48 | 36 | 24 (55%) | 20 (45%) | 0.73 (0.47, 1.12) | 0.80 (0.48, 1.33) | |
| 65+ | 31 | 23 | 17 (55%) | 14 (45%) | 0.90 (0.56, 1.46) | 0.96 (0.55, 1.68) | |
| P value | 0.51 | 0.33 | 0.66 | ||||
| Ethnicity | |||||||
| African American | 5 | 4 | 1 (20%) | 4 (80%) | 1.41 (0.56, 3.55) | 2.31 (0.80, 6.65) | |
| Asian | 27 | 20 | 14 (52%) | 13 (48%) | 1.04 (0.65, 1.68) | 1.31 (0.76, 2.27) | |
| Caucasian | 65 | 49 | 29 (48%) | 32 (52%) | 1 (Reference) | 1 (Reference) | |
| Hispanic | 35 | 27 | 20 (59%) | 14 (41%) | 0.83 (0.52, 1.30) | 0.70 (0.39, 1.25) | |
| P value | 0.41 | 0.65 | 0.086 | ||||
| Karnofsky performance status% | |||||||
| 100 | 17 | 13 | 7 (41%) | 10 (59%) | 1 (Reference) | 1 (Reference) | |
| 90 | 43 | 33 | 27 (64%) | 15 (36%) | 1.60 (0.84, 3.06) | 1.33 (0.64, 2.80) | |
| 80 | 22 | 17 | 10 (45%) | 12 (55%) | 1.98 (0.97, 4.02) | 2.38 (1.03, 5.53) | |
| Missing | 50 | 37 | |||||
| P value | 0.17 | 0.13 | 0.066 | ||||
| Primary tumor site | |||||||
| Colon | 87 | 66 | 45 (54%) | 38 (46%) | 1 (Reference) | 1 (Reference) | |
| Rectosigmoid | 13 | 10 | 3 (25%) | 9 (75%) | 1.28 (0.71, 2.31) | 0.96 (0.43, 2.11) | |
| Rectum | 32 | 24 | 16 (50%) | 16 (50%) | 1.37 (0.88, 2.11) | 1.21 (0.73, 2.01) | |
| P value | 0.18 | 0.32 | 0.74 | ||||
| Histologic differentiation | |||||||
| Well | 2 | 1 | 2 (100%) | 0 (0%) | |||
| Moderate | 94 | 72 | 47 (52%) | 44 (48%) | 1 (Reference)* | 1 (Reference)* | |
| Poor | 31 | 23 | 14 (48%) | 15 (52%) | 1.07 (0.68, 1.68) | 1.63 (0.98, 2.70) | |
| Missing | 5 | 4 | |||||
| P value | 0.60 | 0.76 | 0.056 | ||||
| Tumor stage at diagnosis Stage I | |||||||
| Stage I | 2 | 1 | 1 (50%) | 1 (50%) | |||
| Stage II | 6 | 5 | 3 (50%) | 3 (50%) | |||
| Stage III | 13 | 10 | 6 (46%) | 7 (54%) | 1 (Reference)* | 1 (Reference)* | |
| Stage IV | 110 | 83 | 53 (50%) | 52 (50%) | 1.39 (0.82, 2.36) | 2.11 (1.08, 4.10) | |
| Missing | 1 | 1 | |||||
| P value | 1.00 | 0.22 | 0.022 | ||||
| Metastatic site, n | |||||||
| 1 site | 76 | 58 | 44 (58%) | 31 (43%) | 1 (Reference) | 1 (Reference) | |
| 2+ sites | 56 | 42 | 20 (38%) | 32 (62%) | 1.38 (0.95, 2.01) | 1.72 (1.10, 2.70) | |
| P value | 0.031 | 0.085 | 0.013 | ||||
| Metastatic site, localization | |||||||
| Liver | 98 | 74 | 55 (57%) | 42 (43%) | 0.76 (0.50, 1.17) | 0.94 (0.56, 1.58) | |
| 0.012 | 0.21 | 0.82 | |||||
| Lung | 31 | 23 | 8 (26%) | 23 (74%) | 1.42 (0.92, 2.17) | 1.57 (0.98, 2.53) | |
| 0.002 | 0.10 | 0.059 | |||||
| Peritoneum | 23 | 17 | 7 (35%) | 13 (65%) | 1.18 (0.73, 1.90) | 1.43 (0.81, 2.51) | |
| 0.15 | 0.50 | 0.21 | |||||
| Other | 32 | 24 | 10 (34%) | 19 (66%) | 0.95 (0.62, 1.47) | 1.17 (0.70, 1.96) | |
| P value | 0.059 | 0.83 | 0.55 | ||||
| Chemotherapy backbone | |||||||
| FOLFOX-4 | 66 | 50 | 23 (37%) | 39 (63%) | 1 (Reference) | 1 (Reference) | |
| XELOX | 66 | 50 | 41 (63%) | 24 (37%) | 0.98 (0.68, 1.42) | 1.07 (0.69, 1.67) | |
| P value | 0.005 | 0.91 | 0.75 | ||||
| Hospital | |||||||
| USC | 107 | 81 | 57 (55%) | 46 (45%) | 1 (Reference) | 1 (Reference) | |
| MUG | 25 | 19 | 7 (29%) | 17 (71%) | 1.75 (1.09, 2.81) | 0.84 (0.44, 1.58) | |
| P value | 0.025 | 0.016 | 0.59 | ||||
*
Combined with the above categories for stable estimates.
Abbreviations: USC, University of Southern California; MUG: Medical University of Graz; n, number; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RR, response rate; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.